随着2024年报的陆续披露，江苏上市公司董事长的薪酬也公之于众。 根据wind公开数据，金融小强统计了2024年度江苏A股公司部分高管职位的年度薪酬，以供大家参考。今天我 们发布的是【2024江苏A股公司董事长薪酬排行榜】。 根据榜单来看，药明康德董事长李革以4180万元的薪酬总额蝉联榜首，泰禾股份田晓宏以1051.93万元的年薪 排名第二，此二人也是江苏唯二薪酬突破1000万元的上市公司掌门人。 榜单中，薪酬超过500万元的董事长共有11位，其中医药生物、硬件设备行业占据半壁江山，显示出高新技术 产业对高端管理人才的强吸引力。 半导体行业亦表现亮眼，赛腾股份、通富微电、卓胜微等企业董事长薪酬集中在300万-600万元区间。其中， 孙丰（赛腾股份）以622.17万元位列半导体行业首位，反映江苏在芯片产业链的持续投入与管理层价值认可。 榜单前100名中，仅1位女性董事长上榜，为莫若理（祥生医疗，292.96万元），排名第39位，突显职场性别差 距仍待弥合。 此外，我们可以看出，高学历与高薪酬呈强相关性。李革（药明康德）、宣建生（冠捷科技）、XIAOLIN ZHANG（迪哲医药-U）等博士背景高管占据薪酬金字塔顶 ...

Summary of Key Points Core Viewpoint The article discusses the changes in the secretary positions of A-share listed companies in Wuxi, highlighting the salary rankings of these secretaries for the year 2024, as well as the turnover rate of secretaries in the region. Group 1: Overview of Wuxi A-share Listed Companies - Wuxi has a total of 124 A-share listed companies, with 95 secretaries having served before 2024 [1] - Since the beginning of 2024, there have been 29 new secretaries, resulting in a turnover rate of 23.39%, which is higher than that of Nanjing and Suzhou [1] Group 2: Salary Rankings of Secretaries - The highest-paid secretary in Wuxi for 2024 is Lü Hongbin from Dize Pharmaceutical, with a total salary of 4.21 million yuan, an increase from 4.07 million yuan in 2023 [4][8] - The second highest is Wu Guoyi from China Resources Microelectronics, earning 2.62 million yuan, slightly up from 2.60 million yuan in 2023 [4][8] - Other notable salaries include Yang Erli from Xiexin Energy at 1.86 million yuan and Zhang Yuanzhou from WuXi AppTec at 1.55 million yuan [4][8] Group 3: Notable Secretary Profiles - Lü Hongbin, born in 1978, has a background in investment banking and has held various significant positions in the industry before becoming the secretary at Dize Pharmaceutical [3] - Wu Guoyi, aged 48, has been the secretary at China Resources Microelectronics since April 2019 and is the second highest-paid secretary in Wuxi [3] Group 4: Salary Comparison and Trends - The salary data indicates a general increase in compensation for secretaries compared to the previous year, with several secretaries seeing significant jumps in their earnings [4][8] - The trend of hiring from investment banking for secretary positions continues, reflecting a competitive job market for these roles [3]

中国经济网北京5月12日讯迪哲医药(688192.SH)今日收报52.23元，跌幅7.36%。该股目前处于破发状 态。 迪哲医药于2021年12月10日在上交所科创板上市，发行股票4000.01万股，发行价格为52.58元/股。 迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。迪 哲医药最终募集资金净额比原计划多2.03亿元。该公司于2021年12月7日披露的招股说明书显示，其拟 募集资金17.83亿元，拟分别用于新药研发项目和补充流动资金。 迪哲医药首次公开发行股票的保荐人(主承销商)为中信证券股份有限公司，保荐代表人为丁元、彭浏 用，联席主承销商为华泰联合证券有限责任公司。该公司发行费用总额为1.17亿元，其中，承销费及保 荐费9564.42万元。 迪哲医药4月22日发布的2023年度向特定对象发行A股股票上市公告书显示，根据立信会计师事务所(特 殊普通合伙)2025年4月10日出具的《验资报告》(信会师报字[2025]第ZA10726号)，本次发行最终获配发 行对象共计14名，发行价格为43.00元/股，本次发行数量为41,764,808股，募集资金总额 ...

Core Viewpoint - The article discusses the disparity in employee compensation within the A-share pharmaceutical and biotechnology sector for the year 2024, highlighting the highest and lowest average salaries among companies in the industry. Group 1: Highest Average Salaries - The top ten companies with the highest average employee salaries in the pharmaceutical and biotechnology sector are predominantly innovative drug companies, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - The average salary of BeiGene's R&D personnel is 956,000 yuan, with domestic R&D personnel earning an average of 592,000 yuan and overseas R&D personnel earning 1,586,000 yuan [2] - Other companies in the top ten include Dizal Pharmaceutical (迪哲医药) with an average salary of 686,700 yuan and Yihong Pharmaceutical (亚虹医药) with an average salary of 627,400 yuan [2][3] Group 2: Lowest Average Salaries - The ten companies with the lowest average salaries in the sector have an average salary as low as 70,500 yuan, with the lowest being 70,500 yuan at Yisheng Pharmaceutical (益盛药业) [7][9] - The majority of these low-salary companies are traditional Chinese medicine firms and offline pharmacy businesses, with four being Chinese medicine companies [10] - Companies like Teva Pharmaceutical (特一药业) reported a significant decline in net profit, leading to a 10.1% decrease in average salary compared to 2023 [11] Group 3: Salary Trends and Industry Insights - Among the 498 companies in the pharmaceutical and biotechnology sector, 49 companies have an average salary above 300,000 yuan, while 144 companies fall between 200,000 to 300,000 yuan [8] - The article notes that the average salary for most innovative drug companies has increased compared to 2023, with the highest increase being 13.62% for Ailisi (艾力斯) [6] - The article also highlights the challenges faced by offline pharmacies, with a significant drop in customer traffic and profitability due to changes in healthcare policies and increased competition [11][12]

证券代码：688192 证券简称：迪哲医药 公告编号：2025-30 迪哲（江苏）医药股份有限公司 关于董事兼高级管理人员减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持有的基本情况 本次股份减持计划实施前，迪哲（江苏）医药股份有限公司（以下简称"公 司"）董事长兼首席执行官张小林（ZHANG XIAOLIN）博士直接持有公司股份 7,310,972 股，占公司目前总股本的 1.5913%。上述股份中 7,150,000 股来自股权 激励计划行权，160,972 股来自二级市场集中交易竞价增持。 减持计划的实施结果情况 2025 年 1 月 21 日，公司披露了《迪哲医药：关于董事兼高级管理人员减持 股份计划公告》（公告编号：2025-04）（以下简称"《减持计划"》），因偿 还借款等个人资金需求，张小林博士拟通过集中竞价交易或大宗交易方式合计减 持公司股份不超过 1,827,000 股（含本数），占公司总股本的比例不超过 0.4374%， 自减持计划披露之日起 ...

Core Insights - The pharmaceutical and biotechnology sector in A-shares has revealed significant disparities in employee compensation, with innovative drug companies dominating the highest salary rankings [1][2] Group 1: Highest Employee Compensation - The top ten companies in the pharmaceutical and biotechnology sector for employee compensation in 2024 are primarily innovative drug firms, with BeiGene (百济神州) leading at an average salary of 905,000 yuan [1][2] - Other companies in the top ten include Dizhihua Pharmaceutical (迪哲医药) with 686,700 yuan, Yahui Pharmaceutical (亚虹医药) with 627,400 yuan, and others, with salaries ranging from 480,600 yuan to 905,000 yuan [1][2] Group 2: R&D Personnel Impact - Innovative drug companies have a high proportion of R&D personnel, which contributes to elevated overall salary levels; BeiGene employs approximately 11,100 staff, with 3,905 in R&D, making up about 35% of the workforce [2] - The average salary for R&D personnel at BeiGene is 956,000 yuan, with domestic R&D staff earning 592,000 yuan and international R&D staff earning 1,586,000 yuan [2] Group 3: Lowest Employee Compensation - In contrast, the lowest ten companies in the sector have an average salary as low as 70,500 yuan, with a significant representation from traditional Chinese medicine firms [5][6] - The lowest salaries are reported for companies like Yisheng Pharmaceutical (益盛药业) at 70,500 yuan and others, with the majority of these companies experiencing declines in net profit [5][6] Group 4: Performance Trends - Among the top ten companies, eight have seen an increase in average salaries compared to 2023, with the highest increase at 13.62% for Ailisi (艾力斯) [4] - Ailisi's revenue reached 3.558 billion yuan in 2024, marking a 76.29% increase, while net profit rose by 121.97% to 1.43 billion yuan [4] Group 5: Challenges in the Sector - Companies like Te Yi Pharmaceutical (特一药业) have faced significant challenges, with a 91.9% decline in net profit attributed to changes in marketing strategies and reduced sales of key products [6][7] - The retail pharmacy sector is experiencing a downturn, with companies like Yixin Hall (一心堂) and Shuyuan Pingmin (漱玉平民) reporting over 69% declines in net profit due to increased competition and changes in consumer purchasing behavior [7][8]

保荐总结报告书 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 首次公开发行股票并在科创板上市 之保荐总结报告书 保荐机构名称 华泰联合证券有限责任公司 保荐机构编号 Z26774000 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证券监督管理委员会（以下简称"中国证监 会"）、上海证券交易所对保荐总结报告书相关事项进行的任何质询和调查。 二、保荐机构基本情况 | 情况 | 内容 | | --- | --- | | 保荐机构名称 | 华泰联合证券有限责任公司 | | 注册地址 | 深圳市前海深港合作区南山街道桂湾五路 128 号前海深港基金小 | | | 镇 栋 B7 401 | | 主要办公地址 | 北京市西城区丰盛胡同 22 号丰铭国际大厦 A 座 6 层 | | 法定代表人 | 江禹 | | 联系人 | 许超、丁明明 | | 联系电 ...

根据《证券法》、《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为迪哲（江苏）医药股份有限公司 （以下简称"迪哲医药"或"公司"）2023 年度向特定对象发行 A 股股票的保 荐机构，承接公司首次公开发行的原保荐机构中信证券股份有限公司未完成的持 续督导工作，对迪哲医药进行持续督导，并出具本年度持续督导跟踪报告。 一、保荐机构和保荐代表人发现的问题及整改情况 华泰联合证券有限责任公司 关于迪哲（江苏）医药股份有限公司 2024年年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：迪哲医药 | | --- | --- | | 保荐代表人姓名：许超 | 联系电话：010-56839300 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | 随着研发投入的增加，报告期内公司仍处于亏损状态。公司针对不同靶点研 制多款产品，未来仍需持续较大规模的研发投入用于在研项目完成临床试验、药 学研究、临床前研究及新药上市前准备等产品管线研发业务。此外，公司 ...

Group 1 - Dize Pharmaceutical (688192.SH) reported its Q1 2025 results, with 57 institutional investors holding a total of 334 million shares, representing 80.01% of the company's total equity [1] - The top ten institutional investors collectively hold 73.98% of Dize Pharmaceutical's shares, with a slight increase of 0.11 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 17 funds increased their holdings, accounting for a 0.86% increase, with notable funds including Yongying Medical Innovation Mixed Fund A and Ping An Medical Health Mixed A [2] - Conversely, 13 public funds reduced their holdings, representing a 0.12% decrease, with key funds including Bosera Health Growth and Penghua Innovation Medical Mixed A [2] - Six new public funds disclosed their holdings this period, while 239 funds were not disclosed compared to the previous quarter [2]

Group 1 - The core viewpoint of the articles highlights the significant revenue growth and commercialization progress of DiZhe Pharmaceutical, with a reported revenue of 360 million yuan in 2024, marking a year-on-year increase of 294.24% [1] - The company has successfully launched two commercialized products, which have seen nearly doubled sales revenue, achieving a year-on-year growth of 96% in the first quarter of this year [1] - DiZhe Pharmaceutical has established a competitive product pipeline with seven products, including two that are in global clinical trials and have been approved for marketing in China [1][2] Group 2 - In 2024, the company invested 724 million yuan in R&D, accounting for 201.08% of its revenue, with an additional 210 million yuan spent in the first quarter [2] - The company plans to allocate nearly 1 billion yuan from its recent fundraising to the development of core pipeline drugs, including Shuwotini and DZD8586 [2] - DiZhe Pharmaceutical's innovative drug development is characterized by long cycles and high costs, with potential uncertainties in future sales revenue due to various market factors [3] Group 3 - The company is expected to remain unprofitable in the short term, with cumulative losses likely to increase due to ongoing investments in drug registration and market promotion [3] - Analysts believe that DiZhe Pharmaceutical's focus on oncology and innovative products will drive rapid growth in performance as commercialized products gain market traction [3]